Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander I Spira

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2022
Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION StudySamuel Rosner, Alexander I Spira
The Oncologist|August 20, 2002
The use of chemotherapy in soft-tissue sarcomasAlexander I Spira, David S Ettinger
Current Opinion in Pharmacology|August 7, 2003
Differentiation therapyAlexander I Spira, Michael A Carducci
The New England Journal of Medicine|February 5, 2025
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. ReplyByoung C Cho, Seema Sethi, Alexander I Spira
The New England Journal of Medicine|September 28, 2022
Adagrasib in Non-Small-Cell Lung Cancer. ReplyPasi A Jänne, Joshua K Sabari, Alexander I Spira
Anti-Cancer Drugs|September 11, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancerKara M Schenk, Joshua E Reuss, Karin Choquette, et al.
Clinical Lung Cancer|December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLCAlexander I Spira, David Berz, Robert M Jotte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2025
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"Matthew G Krebs, Byoung Chul Cho, Priya Kim, et al.
Advances in Therapy|May 29, 2025
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended TherapyAlexander I Spira, Tao Ran, Iris Lin, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancerBryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2022
Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION StudySamuel Rosner, Alexander I Spira
The Oncologist|August 20, 2002
The use of chemotherapy in soft-tissue sarcomasAlexander I Spira, David S Ettinger
Current Opinion in Pharmacology|August 7, 2003
Differentiation therapyAlexander I Spira, Michael A Carducci
The New England Journal of Medicine|February 5, 2025
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. ReplyByoung C Cho, Seema Sethi, Alexander I Spira
The New England Journal of Medicine|September 28, 2022
Adagrasib in Non-Small-Cell Lung Cancer. ReplyPasi A Jänne, Joshua K Sabari, Alexander I Spira
Anti-Cancer Drugs|September 11, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancerKara M Schenk, Joshua E Reuss, Karin Choquette, et al.
Clinical Lung Cancer|December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLCAlexander I Spira, David Berz, Robert M Jotte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2025
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"Matthew G Krebs, Byoung Chul Cho, Priya Kim, et al.
Advances in Therapy|May 29, 2025
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended TherapyAlexander I Spira, Tao Ran, Iris Lin, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancerBryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Pageof 8